Gilead Sciences, Inc. (NASDAQ:GILD)

For reference point and to allow for comments by others. As of the end of March, 2013.

ROE 32.14%
Trailing PE 31.52
PB 8.06
Div yield N/A

Unbeatable.

s&p 5 star

Best of breed pharm (lil pfizer)

Progress in Gilead's oral treatment of hepatitis C could mean an extremely lucrative addition to its pipeline given future FDA approval

good products, growth industry

Good run in March-April; time to do it again!

(Excellent HIV drug in the pipeline) + (Recommended by Cramer) + (recommended by 556 of 563 CAPS all stars) + (Up 100% in a year and chart shows no sign of letting up) = (I'm in).

April 17, 2013 update: Seemingly unstoppable chart pattern continues. Possible topping, in the last few days; but given that this is while the market is falling, it looks more likely GILD is continuing up.

Strong fundamentals reflect solid management. Creates value that the world needs.

A++

Fresh drug pipeline, good fundamental, and even better patent protections for a series of drugs targeted at diseases that have very limited medication alternative.

Sounds like Monopoly?

(Please tear apart this statement - I love a healthy discussion on this stock as I own it in real life)

TMFUltraLong

outperform

Good pipeline

Hep C drug coming through this summer! Will be very large profit potential.

Nasdaq in maximums.

HCV Franchise adds significant growth potential going into 2014

No balm in Tamiflu, according to recent meta-analyses. Company is concealing the relevant data.

Once a day HIV drug is a hit.... Hep C market is brand new and could be in excess of $10 billion.... Gilead is going to be a market leader with a high cure rate and less infection.

Gilead Sciences Inc. (NASDAQ: GILD) was surprising to see on the list because this winner of HIV and Hepatitis C was one of the best 10 S&P 500 stocks of 2012 so far. It is always interesting when a prior winner is selected again, particularly when this has a $56 billion market cap. At $74.40, its 52-week range is $36.98 to $76.28. The consensus price target of $82.50 offers an implied upside of about 11%. No ongoing dividend here.